While therapies that block caspase-1 have failed, knocking out GSDMD in murine models of CAPS, and FMF prevented disease development (21, 22), suggesting GSDMD as a potential treatment target. The gene discussed is GSDMD; the disease is cryopyrin-associated periodic syndrome.